Canada's Knight Therapeutics Q2 revenue beats on growth in promoted portfolio

Knight Therapeutics

06/08/2026 11:41

Overview
Canada pharmaceutical firm's Q2 revenue rose 34% yr/yr, beating analyst expectations
Adjusted EBITDA grew 58% yr/yr, driven by promoted products and recent launches
Company raised 2026 revenue guidance to C$540-C$560 mln on strong promoted portfolio

Outlook
Knight raises 2026 revenue guidance to C$540 mln-C$560 mln from C$510 mln-C$525 mln
Company expects 2026 adjusted EBITDA to be at least 15% of revenues
Knight says Lenvima price controls and generics expected to negatively impact Colombia sales

Result Drivers
PROMOTED PRODUCTS - Growth in promoted portfolio, including newly launched pipeline products, drove revenue increase
RECENT LAUNCHES - Seventeen product launches since January 2024, including four in Q2, contributed to revenue growth
CURRENCY IMPACT - Appreciation of select LATAM currencies against the Canadian dollar helped boost reported revenues

Company press release: ID:nGNX4Jghgp

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
C$144.21 mln
C$124.97 mln (6 Analysts)
Q2 Net Loss
 
C$3.36 mln
 
Q2 Operating Expenses
 
C$60.66 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Knight Therapeutics Inc is C$9.50, about 2.6% above its August 5 closing price of C$9.26
The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 39 three months ago

Reuters Recommended Reads
Aug 5 - Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales
Aug 6 - Prestige Consumer Healthcare beats Q1 revenue estimates, raises 2027 outlook
Aug 4 - Merck posts better-than-expected second-quarter results on Keytruda strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)